MedTrace Logo

Gallium-68 DOTATOC for Management of Neuroendocrine Tumors

NCT02375464 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2016-11-08

No results posted yet for this study

Summary

Gallium-68 DOTATOC is a material used to find neuroendocrine tumors (NETs) using positron emission tomography (PET scan). The material has already been shown to be better than the currently available imaging agents. This study is designed to evaluate the clinical impact of PET CT scanning using this agent in the evaluation and management of patients with NETs.

Conditions

Interventions

DRUG

Gallium-68 DOTATOC

Imaging with Gallium-68 DOTATOC

Sponsors & Collaborators

  • Northwell Health

    lead OTHER

Principal Investigators

  • STEPHEN C SCHARF, MD · Lenox Hill Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2018-12-31
Completion
2019-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02375464 on ClinicalTrials.gov